PCM
TLSI icon

PenderFund Capital Management’s TriSalus Life Sciences TLSI Stock Holding History

PenderFund Capital Management’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,768
Closed -$25K – 113
2023
Q2 		$25K Buy
+1,768
New +$18.4K 0.01% 102

Other funds holding TLSI

CWM
Connecticut Wealth Management Farmington, Connecticut $2.7B AUM 21.91% 1-Year Est. Return
AC
Anson Capital Tyrone, Georgia $154M AUM 17.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
GWSG
GPS Wealth Strategies Group Centennial, Colorado $117M AUM 24.22% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

PenderFund Capital Management's TLSI Position: Q3 2023 in Review

PenderFund Capital Management sold out of TriSalus Life Sciences (TLSI) in Q3 2023, closing a stake of 1,768 shares — an estimated $25K sold.

PenderFund Capital Management first reported a position in TLSI in Q2 2023 and held it in 1 quarter. The position peaked at $25K in Q2 2023. 9 funds tracked by Wall St. Rank hold TLSI as of Q3 2023.

  • PenderFund Capital Management reported no remaining TriSalus Life Sciences position as of Q3 2023 after selling out during the quarter.
  • PenderFund Capital Management sold 1,768 TriSalus Life Sciences shares in Q3 2023, an estimated $25K.
  • PenderFund Capital Management first reported a position in TriSalus Life Sciences in Q2 2023 and held it in 1 quarter.
  • PenderFund Capital Management's TriSalus Life Sciences position peaked at $25K in Q2 2023.
  • 9 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q3 2023.

Based on PenderFund Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.